Agilent Technologies, Inc. (0HAV.L)
USD 136.25
(-0.67%)
USD 136.25
(-0.67%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 1.35 Billion USD | -16.56% |
| 2022 | 1.61 Billion USD | 20.12% |
| 2021 | 1.34 Billion USD | 59.22% |
| 2020 | 846 Million USD | -10.1% |
| 2019 | 941 Million USD | 1.4% |
| 2018 | 928 Million USD | 10.34% |
| 2017 | 841 Million USD | 36.75% |
| 2016 | 615 Million USD | 17.82% |
| 2015 | 522 Million USD | -37.18% |
| 2014 | 831 Million USD | -12.62% |
| 2013 | 951 Million USD | -15.01% |
| 2012 | 1.11 Billion USD | 4.48% |
| 2011 | 1.07 Billion USD | 89.22% |
| 2010 | 566 Million USD | 1104.26% |
| 2009 | 47 Million USD | -94.09% |
| 2008 | 795 Million USD | 36.13% |
| 2007 | 584 Million USD | 25.86% |
| 2006 | 464 Million USD | 156.35% |
| 2005 | 181 Million USD | -53.11% |
| 2004 | 386 Million USD | 153.24% |
| 2003 | -725 Million USD | 54.88% |
| 2002 | -1.6 Billion USD | -106.56% |
| 2001 | -778 Million USD | -173.88% |
| 2000 | 1.05 Billion USD | 42.11% |
| 1999 | 741 Million USD | 67.65% |
| 1998 | 442 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | 363 Million USD | -9.25% |
| 2024 Q3 | 333 Million USD | -8.26% |
| 2024 Q1 | 400 Million USD | -1.96% |
| 2023 FY | 1.35 Billion USD | -16.56% |
| 2023 Q3 | 133 Million USD | -65.27% |
| 2023 Q1 | 426 Million USD | -9.55% |
| 2023 Q2 | 383 Million USD | -10.09% |
| 2023 Q4 | 408 Million USD | 206.77% |
| 2022 Q1 | 376 Million USD | -4.81% |
| 2022 Q3 | 411 Million USD | 14.17% |
| 2022 FY | 1.61 Billion USD | 20.12% |
| 2022 Q4 | 471 Million USD | 14.6% |
| 2022 Q2 | 360 Million USD | -4.26% |
| 2021 Q4 | 395 Million USD | 17.56% |
| 2021 Q1 | 328 Million USD | 9.7% |
| 2021 Q2 | 288 Million USD | -12.2% |
| 2021 Q3 | 336 Million USD | 16.67% |
| 2021 FY | 1.34 Billion USD | 59.22% |
| 2020 Q2 | 102 Million USD | -52.56% |
| 2020 Q4 | 299 Million USD | 30.0% |
| 2020 FY | 846 Million USD | -10.1% |
| 2020 Q3 | 230 Million USD | 125.49% |
| 2020 Q1 | 215 Million USD | -14.0% |
| 2019 FY | 941 Million USD | 1.4% |
| 2019 Q4 | 250 Million USD | 11.11% |
| 2019 Q3 | 225 Million USD | 4.17% |
| 2019 Q2 | 216 Million USD | -13.6% |
| 2019 Q1 | 250 Million USD | 0.4% |
| 2018 Q4 | 249 Million USD | 10.67% |
| 2018 Q1 | 239 Million USD | 2.58% |
| 2018 Q3 | 225 Million USD | 4.65% |
| 2018 Q2 | 215 Million USD | -10.04% |
| 2018 FY | 928 Million USD | 10.34% |
| 2017 Q1 | 206 Million USD | 12.57% |
| 2017 Q4 | 233 Million USD | 15.92% |
| 2017 Q3 | 201 Million USD | 0.0% |
| 2017 FY | 841 Million USD | 36.75% |
| 2017 Q2 | 201 Million USD | -2.43% |
| 2016 FY | 615 Million USD | 17.82% |
| 2016 Q4 | 183 Million USD | 25.34% |
| 2016 Q2 | 131 Million USD | -15.48% |
| 2016 Q1 | 155 Million USD | -0.64% |
| 2016 Q3 | 146 Million USD | 11.45% |
| 2015 Q4 | 156 Million USD | 8.33% |
| 2015 Q2 | 107 Million USD | -6.96% |
| 2015 Q1 | 115 Million USD | -33.91% |
| 2015 FY | 522 Million USD | -37.18% |
| 2015 Q3 | 144 Million USD | 34.58% |
| 2014 FY | 831 Million USD | -12.62% |
| 2014 Q3 | 229 Million USD | 9.05% |
| 2014 Q4 | 174 Million USD | -24.02% |
| 2014 Q1 | 218 Million USD | -23.51% |
| 2014 Q2 | 210 Million USD | -3.67% |
| 2013 FY | 951 Million USD | -15.01% |
| 2013 Q2 | 213 Million USD | -1.84% |
| 2013 Q3 | 236 Million USD | 10.8% |
| 2013 Q4 | 285 Million USD | 20.76% |
| 2013 Q1 | 217 Million USD | -21.94% |
| 2012 FY | 1.11 Billion USD | 4.48% |
| 2012 Q4 | 278 Million USD | 2.96% |
| 2012 Q3 | 270 Million USD | -10.0% |
| 2012 Q2 | 300 Million USD | 10.7% |
| 2012 Q1 | 271 Million USD | -13.42% |
| 2011 FY | 1.07 Billion USD | 89.22% |
| 2011 Q3 | 281 Million USD | 5.64% |
| 2011 Q1 | 211 Million USD | 3.94% |
| 2011 Q2 | 266 Million USD | 26.07% |
| 2011 Q4 | 313 Million USD | 11.39% |
| 2010 Q4 | 203 Million USD | 76.52% |
| 2010 Q3 | 115 Million USD | -25.32% |
| 2010 Q2 | 154 Million USD | 63.83% |
| 2010 FY | 566 Million USD | 1104.26% |
| 2010 Q1 | 94 Million USD | 32.39% |
| 2009 Q4 | 71 Million USD | 7200.0% |
| 2009 FY | 47 Million USD | -94.09% |
| 2009 Q1 | 24 Million USD | -90.48% |
| 2009 Q2 | -47 Million USD | -295.83% |
| 2009 Q3 | -1 Million USD | 97.87% |
| 2008 FY | 795 Million USD | 36.13% |
| 2008 Q1 | 134 Million USD | -29.47% |
| 2008 Q3 | 218 Million USD | 14.14% |
| 2008 Q2 | 191 Million USD | 42.54% |
| 2008 Q4 | 252 Million USD | 15.6% |
| 2007 Q2 | 131 Million USD | 37.89% |
| 2007 Q4 | 190 Million USD | 13.1% |
| 2007 Q3 | 168 Million USD | 28.24% |
| 2007 Q1 | 95 Million USD | -5.0% |
| 2007 FY | 584 Million USD | 25.86% |
| 2006 Q2 | 112 Million USD | 148.89% |
| 2006 Q3 | 207 Million USD | 84.82% |
| 2006 Q4 | 100 Million USD | -51.69% |
| 2006 FY | 464 Million USD | 156.35% |
| 2006 Q1 | 45 Million USD | 152.94% |
| 2005 Q3 | 89 Million USD | 8.54% |
| 2005 Q4 | -85 Million USD | -195.51% |
| 2005 FY | 181 Million USD | -53.11% |
| 2005 Q1 | 95 Million USD | 6.74% |
| 2005 Q2 | 82 Million USD | -13.68% |
| 2004 Q4 | 89 Million USD | -16.82% |
| 2004 Q3 | 107 Million USD | -3.6% |
| 2004 Q1 | 79 Million USD | 41.07% |
| 2004 FY | 386 Million USD | 153.24% |
| 2004 Q2 | 111 Million USD | 40.51% |
| 2003 Q1 | -256 Million USD | 33.85% |
| 2003 FY | -725 Million USD | 54.88% |
| 2003 Q4 | 56 Million USD | 129.47% |
| 2003 Q3 | -190 Million USD | 43.28% |
| 2003 Q2 | -335 Million USD | -30.86% |
| 2002 FY | -1.6 Billion USD | -106.56% |
| 2002 Q4 | -387 Million USD | 9.79% |
| 2002 Q3 | -429 Million USD | -22.92% |
| 2002 Q2 | -349 Million USD | 21.04% |
| 2002 Q1 | -442 Million USD | 32.83% |
| 2001 Q1 | 279 Million USD | -39.08% |
| 2001 Q4 | -658 Million USD | -92.4% |
| 2001 Q3 | -342 Million USD | -451.61% |
| 2001 Q2 | -62 Million USD | -122.22% |
| 2001 FY | -778 Million USD | -173.88% |
| 2000 Q3 | 210 Million USD | -1.87% |
| 2000 Q1 | 171 Million USD | 103.33% |
| 2000 FY | 1.05 Billion USD | 42.11% |
| 2000 Q2 | 214 Million USD | 25.15% |
| 2000 Q4 | 458 Million USD | 118.1% |
| 1999 Q4 | -5.14 Billion USD | -346.38% |
| 1999 Q3 | 2.08 Billion USD | 3.83% |
| 1999 FY | 741 Million USD | 67.65% |
| 1999 Q2 | 2.01 Billion USD | 12.54% |
| 1999 Q1 | 1.78 Billion USD | 0.0% |
| 1998 FY | 442 Million USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Editas Medicine, Inc. | -169.18 Million USD | 897.962% |
| Dynavax Technologies Corporation | -37.02 Million USD | 3745.89% |
| Supernus Pharmaceuticals, Inc. | -5.26 Million USD | 25721.56% |
| Perrigo Company plc | 151.9 Million USD | -788.743% |
| Illumina, Inc. | -1.06 Billion USD | 226.286% |
| Thermo Fisher Scientific Inc. | 6.85 Billion USD | 80.318% |
| Iovance Biotherapeutics, Inc. | -460.55 Million USD | 393.122% |
| Walgreens Boots Alliance, Inc. | -14.07 Billion USD | 109.591% |
| IQVIA Holdings Inc. | 1.97 Billion USD | 31.715% |
| Heron Therapeutics, Inc. | -110.61 Million USD | 1320.449% |
| Regeneron Pharmaceuticals, Inc. | 4.04 Billion USD | 66.643% |
| Unity Biotechnology, Inc. | -44.66 Million USD | 3122.366% |
| Waters Corporation | 817.67 Million USD | -65.102% |
| Biogen Inc. | 1.29 Billion USD | -4.102% |
| Sangamo Therapeutics, Inc. | -274 Million USD | 592.692% |
| Evolus, Inc. | -49.23 Million USD | 2842.063% |
| Adicet Bio, Inc. | -152.03 Million USD | 987.936% |
| Cara Therapeutics, Inc. | -121.49 Million USD | 1211.157% |
| bluebird bio, Inc. | -244.26 Million USD | 652.685% |
| Esperion Therapeutics, Inc. | -155.56 Million USD | 967.816% |
| FibroGen, Inc. | -281.81 Million USD | 579.038% |
| Corbus Pharmaceuticals Holdings, Inc. | -45.07 Million USD | 3094.855% |
| Homology Medicines, Inc. | -48.25 Million USD | 2897.638% |
| Geron Corporation | -193.94 Million USD | 796.077% |
| Alnylam Pharmaceuticals, Inc. | -282.17 Million USD | 578.427% |
| Amicus Therapeutics, Inc. | -73.49 Million USD | 1936.885% |
| Myriad Genetics, Inc. | -123.7 Million USD | 1191.35% |
| Viking Therapeutics, Inc. | -100.82 Million USD | 1438.927% |
| Intellia Therapeutics, Inc. | -515.29 Million USD | 361.988% |
| Zoetis Inc. | 3.06 Billion USD | 56.012% |
| Abeona Therapeutics Inc. | -48.2 Million USD | 2900.83% |
| Mettler-Toledo International Inc. | 1.08 Billion USD | -24.163% |
| BioMarin Pharmaceutical Inc. | 194.44 Million USD | -594.298% |
| Vertex Pharmaceuticals Incorporated | 4.3 Billion USD | 68.659% |
| Kala Pharmaceuticals, Inc. | -39.15 Million USD | 3548.012% |
| Ionis Pharmaceuticals, Inc. | -353.73 Million USD | 481.647% |
| Atara Biotherapeutics, Inc. | -276 Million USD | 589.12% |
| Verastem, Inc. | -92.08 Million USD | 1566.053% |
| Nektar Therapeutics | -137.42 Million USD | 1082.354% |
| Axsome Therapeutics, Inc. | -231.82 Million USD | 682.336% |
| Aclaris Therapeutics, Inc. | -97.35 Million USD | 1486.649% |
| Sarepta Therapeutics, Inc. | -267.82 Million USD | 604.062% |
| OPKO Health, Inc. | -157.02 Million USD | 959.758% |
| Exelixis, Inc. | 170.88 Million USD | -690.005% |
| Neurocrine Biosciences, Inc. | 250.9 Million USD | -438.063% |
| Corcept Therapeutics Incorporated | 107.28 Million USD | -1158.366% |
| Anavex Life Sciences Corp. | -55.75 Million USD | 2521.264% |
| uniQure N.V. | -282.87 Million USD | 577.249% |
| Imunon, Inc. | -21.03 Million USD | 6519.27% |
| Blueprint Medicines Corporation | -486.27 Million USD | 377.62% |
| Insmed Incorporated | -709.62 Million USD | 290.241% |
| Halozyme Therapeutics, Inc. | 337.57 Million USD | -299.912% |
| Agios Pharmaceuticals, Inc. | -391.48 Million USD | 444.839% |
| TG Therapeutics, Inc. | 20.63 Million USD | -6442.917% |
| Incyte Corporation | 620.52 Million USD | -117.558% |
| Emergent BioSolutions Inc. | -726.4 Million USD | 285.848% |